{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-002975","form_type":"8-K","ticker":null,"cik":"0001017491","company_name":"SEELOS THERAPEUTICS, INC.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.114523+00:00","generated_at":"2026-06-07T00:48:09.668272+00:00","sec_items":["3.03","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Seelos shareholders approve 25x increase in authorized shares, ratify Lind Global note issuance","bullets":["Authorized common shares increased from 16M to 400M via Certificate of Amendment filed Jan 10, 2024.","Stockholders approved issuance of >20% of outstanding common stock under $22M convertible note with Lind Global (Convertible Note Proposal).","Vote on authorized share increase: 5,189,686 for, 1,101,134 against, 27,944 abstain.","Vote on convertible note proposal: 3,005,989 for, 698,838 against, 1,051,469 abstain, 1,562,468 broker non-votes.","Amendment does not alter voting rights but enables future dilution from additional share issuances."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-002975","json":"https://secwatch.observer/filing/0001104659-24-002975.json","markdown":"https://secwatch.observer/filing/0001104659-24-002975.md","text":"https://secwatch.observer/filing/0001104659-24-002975.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1017491/000110465924002975/0001104659-24-002975-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1017491/000110465924002975/tm242612d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:48:09.668272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87eebca301c10c9385f3ed3d6392358c9aaf9279","claim":"SEELOS THERAPEUTICS, INC.: Increased authorized shares of common stock from 16,000,000 to 400,000,000 via a Certificate of Amendment to the Amended and Restated Articles of Incorporation (effective 2024-01-10).","evidence_excerpt":"On January 10, 2024, the Company filed a Certificate of Amendment to the Articles (the “Certificate of Amendment”) with the Secretary of State of the State of Nevada to increase the number of authorized shares of Common Stock from 16,000,000 to 400,000,000.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1017491/000110465924002975/0001104659-24-002975-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-01-10"}],"fact_type":"governance_change"},{"claim_id":"c34ebda60a7892a11ef9f1b7575c6d0b903b1db2","claim":"SEELOS THERAPEUTICS, INC. shareholders approved To approve an amendment to the Articles to increase the number of authorized shares of common stock to a total of 400,000,000 (Authorized Share Increase Proposal). at the 2024-01-10 meeting.","evidence_excerpt":"Proposal No. 2: To approve an amendment to the Articles to increase the number of authorized shares of common stock to a total of 400,000,000 (the “Authorized Share Increase Proposal”). For Against Abstentions 5,189,686 1,101,134 27,944","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1017491/000110465924002975/0001104659-24-002975-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-10"}],"fact_type":"shareholder_vote"},{"claim_id":"d5710b05ee3d6c9374d8e4cd3b90798eff400b65","claim":"SEELOS THERAPEUTICS, INC. shareholders approved To approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes to approve the other proposals. at the 2024-01-10 meeting.","evidence_excerpt":"Proposal No. 3: To approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve the Convertible Note Proposal and/or the Authorized Share Increase Proposal. For Against Abstentions 5,284,077 984,296 50,391","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1017491/000110465924002975/0001104659-24-002975-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-10"}],"fact_type":"shareholder_vote"},{"claim_id":"d6d1ce8a0780b1bdb30a51e7090c0f8e146e68cf","claim":"SEELOS THERAPEUTICS, INC. shareholders approved To approve the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to certain convertible notes and agreements with Lind Global (Convertible Note Proposal). at the 2024-01-10 meeting.","evidence_excerpt":"Proposal No. 1: To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to: (a) that certain Convertible Promissory Note No. 1 in the initial principal amount of $22,000,000 and due November 23, 2024, issued by the Company to Lind Global Asset Management V, LLC (“Lind Global”) on November 23, 2021, as amended on December 10, 2021, on February 8, 2023, on May 19, 2023 and September 30, 2023, (b) that certain securities purchase agreement, dated November 23, 2021, by and between the Company and Lind Global, and (c) that certain Letter Agreement, dated September 21, 2023, by and between the Company and Lind Global, as amended by that certain Amendment No. 4 to Convertible Promissory Note and Amendment to Letter Agreement, effective September 30, 2023, by and between the Company and Lind Global (the “Convertible Note Proposal”). For Against Abstentions Broker Non-Votes 3,005,989 698,","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1017491/000110465924002975/0001104659-24-002975-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-10"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}